). To confirm the importance of the N-terminal α helix (H1), a fragment expressing the N terminus of MA up to residue 19 demonstrated interaction in yeast (pGBKT7-H1), while a specific deletion of this same fragment failed to bind to the AP-3 δ subunit ( Figure 1D ). An N-terminal fragment of MA truncated after residue 12 failed to interact (data not shown). We conclude that the N-terminal α helix of MA, a region previously implicated in Gag trafficking (Ono et al., 2000) , is the binding site for the AP-3 δ subunit.
We next sought to verify the Gag-AP-3 δ interaction using recombinant Gag protein produced in E. coli. Gag-GST fusion constructs were prepared and evaluated for binding to the AP-3 δ subunit from 293T cell lysates. No interaction was seen with GST alone or with GST fusions with CA, NC, or p6 ( Figure 2A ). Cellular AP-3 δ bound to full-length GST-Gag, Gag lacking p6 (GST-MACANC), Gag lacking NC and p6 (GST-MACA), and with GST-MA alone ( Figure 2A) . A purified protein We next performed experiments designed to investigate the biological significance of the Gag-AP-3 interaction. We reasoned that expression of a fragment of AP-3 δ overlapping the Gag binding domain (AP-3D-5#) could block the interaction of Gag with the endogenous AP-3 complex. To study the effects of this molecule on particle formation, we expressed AP-3D-5# together with pNL4-3 in 293T cells and measured particle release by p24 antigen ELISA. AP-3D-5# expression inhibited particle assembly/release from 293T cells in a manner similar to that of a dominant-negative TSG101 construct ( Figure 4A ). AP-3D-5# demonstrated a significant inhibition of particle release by a Gag/protease expression construct ( Figure 4B ), eliminating the possibility that Env or additional viral gene products are required for AP-3D-5#-mediated inhibition of assembly. The inhibitory effect of AP-3D-5# was dose dependent ( Figure 4C ). Western blotting of cell lysates and of pelleted virion particles revealed an AP-3D-5# dose-dependent decrease in released p24 antigen corresponding to the ELISA results ( Figure 4D ). We considered the possibility that the inhibition of particle release seen upon overexpression of AP-3D-5# was due to cellular toxicity or enhanced degradation of Pr55 Gag . However, intracellular levels of Pr55
Gag and of endogenous AP-3 δ subunit did not decrease substantially at ratios of pression of a C-terminal fragment of AP-3 δ subunit that lacked the Gag interaction domain (AP-3D-3#, Figure  4E ). Taken together, these data demonstrate that APof TSG101 that includes the p6 binding region, was co-3D-5# acts as a dominant-negative inhibitor of asprecipitated with Gag-myc in this assay as a positive sembly. control. The reciprocal immunoprecipitation was then performed and again demonstrated the coimmunoprecipitation of Gag-myc with HA-AP-3D-5# ( Figure 3B) .
Depletion of the AP-3 Complex Inhibits HIV Particle Assembly In order to detect the interaction of Gag with endogenous AP-3 in mammalian cells, immunoprecipitation of To further define the role of the AP-3 complex in HIV particle assembly, we depleted the cellular AP-3 comGag-myc was performed using an anti-myc monoclonal antibody followed by immunoblotting for the AP-3 δ plex from 293T or HeLa cells using siRNA techniques. To achieve a significant depletion of the AP-3 complex subunit. Gag-myc precipitated the full-length endogenous AP-3 δ subunit ( Figure 3C ). In contrast, a particlein 293T cells, we expressed siRNA for both the δ and subunits of the complex and transfected 293T cells competent Gag-myc construct bearing the v-src myristylation signal and lacking MA failed to precipitate the with the combined siRNA at two time points. In cells cotransfected with pNL4-3 following a single treatment AP-3 δ subunit (Src⌬MAGag-myc, lane 3 of Figure 3C ). To further examine this interaction, full-length proviral with siRNA, particle release was inhibited by more than 50% as compared with cells receiving control siRNA DNA (pNL4-3) was transfected into HeLa cells, then Gag was immunoprecipitated using an anti-CA mono-( Figure 5A, T1) . A second treatment with siRNA resulted in enhanced depletion of the and δ subunits, and parclonal antibody. The endogenous AP-3 δ subunit coprecipitated with Gag ( Figure 3D ). These results demonticle release was inhibited by more than 80% as compared with transfection of control siRNA ( Figure 5A , T2). strate that Gag interacts with the AP-3 δ subunit in mammalian cells when Gag alone is expressed and in The progressive depletion of particle release corresponded to enhanced depletion of endogenous AP-3 the context of expression of an infectious provirus. Figure 6V demonstrates that the punctate and plasma membrane patterns of Gag were prominent in cells expressing Gag-CFP alone, while the diffuse pattern was the dominant phenotype in cells expressing the dominant-negative inhibitor. We noted that a subset of cells exhibited a plasma membrane distribution of Gag even sults could reflect an effect of AP-3D-5# on late endosomal trafficking in general. However, AP-3D-5# expression did not alter the plasma membrane expression of CD63 as quantified by flow cytometry, and the lysosomal enzyme cathepsin D was processed in the lysosome at normal levels ( Figure S2 ), indicating that late endosomal trafficking remained intact in the presence of the dominant-negative inhibitor.
Dominant-Negative Inhibition of the Gag-AP-3 Interaction Creates an Assembly Block Distinct from that of TSG-5
We used transmission electron microscopy to define the stage of the block to assembly introduced by AP-3D-5# and compared it with TSG-5#. Normal particle budding was readily observed in 293T cells expressing the NL4-3 provirus in control experiments ( Figures 7A  and 7B ). Cells transfected with pNL4-3 and TSG-5# demonstrated prominent particle buds that were arrested at the plasma membrane, as previously reported for a late budding defect ( Figure 7C ). In cells transfected with pNL4-3 and AP-3D-5# at a 1:1 ratio, in contrast, very few budding particles were observed (illustrated by the cell shown in Figure 7D ). To provide some quantitation of this observation, we examined 100 consecutive cells prepared for thin-section electron microscopy expressing NL4-3 alone, NL4-3 with TSG-5#, or NL4-3 with AP-3D-5#. Of 100 consecutive cells counted, we observed 10 cells with obvious particle budding in pNL4-3-transfected preparations, 12 in cells expressing NL4-3 and TSG-5# at a 1:1 ratio, and 0 cells demonstrating particle budding from preparations expressing NL4-3 and AP-3D-5#. We were able to find rare cells demonstrating particle budding in cells expressing NL4-3 and AP-3D-5# only after examining several 
(A-L) AP-3D-5# inhibits Gag-CD63 colocalization. At early time points, Gag is seen predominantly at intracellular sites (A) and colocalizes with CD63 (E and overlay, I). In the presence of YFP-AP-3D-5#, even those cells demonstrating punctate Gag-CFP (B) do not demonstrate colocalization with CD63 (F and overlay, J). Similarly, Gag was detected by immunostaining in a pattern that colocalized extensively with CD63 (C, G, and overlay, K). YFP-AP-3D-5# expression inhibited colocalization (D, H, and overlay, L). (M) Quantitation of Gag-CFP/CD63 colocalization over time. The percentage of Gag-CFP colocalizing with CD63 was quantified using the MetaMorph software application for 25 evaluable cells in the Gag-CFP alone arm and 25 cells in the Gag-CFP + YFP-AP-3D-5# arm for each time point. Error bars = SEM; p values were derived by paired t test. (N) Quantitation of Gag/CD63 colocalization. Data were collected as in (M), from cells immunostained for Gag and CD63. (O) YFP image of a pair of cells expressing Gag-CFP and YFP-AP-3D-5#. (P) Gag-CFP (green) + CD63 (red) image of same pair of cells depicted in (O). (Q) YFP image of a pair of cells expressing Gag-CFP and YFP-AP-3D-5#. (R) CFP image of the same pair of cells as (Q). (S) Plasma membrane pattern of Gag-CFP. (T) Intracellular

MVBs for YFP-AP-3D-5#-treated cells). Thus, in this cell type, AP-3D-5# blocked particle
Our experiments demonstrate that HIV-1 Gag binds to the δ subunit of the AP-3 complex. The extreme N terformation at the plasma membrane and at intracellular sites but did not disrupt the formation of MVBs. We minus of the MA region bound specifically to the hinge region of the δ subunit, and Gag constructs lacking MA noted that at late time points postinduction, the high level of Gag expression was able to overcome the effailed to interact with AP-3. Particle formation by wildtype Gag was substantially diminished by a dominantfect of AP-3D-5#, and both intracellular and plasma membrane particle assembly could be restored in these negative AP-3δ fragment and by siRNA depletion of AP-3, indicating that the Gag-AP-3 interaction is part cells (data not shown). We conclude that AP-3D-5# blocked trafficking of Gag to MVBs, as revealed by imof the normal productive trafficking pathway of Gag in the cell. The trafficking of Gag to CD63-positive intramunofluorescence, and that particle formation at both intracellular and plasma membrane sites was inhibited cellular compartments was effectively eliminated by the disruption of the Gag-AP-3 interaction. Substitution of by blocking this pathway. Finally, we examined the effect of AP-3D-5# on the behavior of NL4-3 bearing a the myristyl anchor from v-src for MA allowed efficient particle formation in the presence of the dominantlarge deletion in MA, a construct previously shown to bud predominantly into the endoplasmic reticulum negative inhibitor of the Gag-AP-3 interaction, suggesting that this modification takes Gag to the plasma in Cos-7 cells (Facke et al., 1993) . Expression of AP-membrane via a distinct pathway. These findings illumi-MVB is followed by viral budding into the lumen of the MVB. The intact viral particles within the MVB or "viral nate a previously undescribed early step in the HIV assembly pathway.
exosome" may be transported subsequently to the cell surface for release. PIPES, 1 mM EDTA, 3% PEG6000, pH 6.9), permeabilized with A stably transduced 293 cell line expressing Gag and Env from a 0.1% Triton X-100, and blocked with 5% bovine serum albumin. tetracycline-inducible promoter was created using the RevTet vecCells were incubated with mouse anti-Lamp-3 (1:100, Santa Cruz), tor system (Clontech). This cell line (293/Gag-Env) incorporates cowashed, and incubated with goat anti-mouse Alexa 546-conjudon-optimized gag and env genes separated by an internal ribogated antibodies (1:3000, Molecular Probes). In some experiments, some entry site under the control of the tetracycline-responsive Gag staining was performed with polyclonal anti-p17 antisera (Varpromoter for coordinated, inducible expression of Gag and Env. thakavi et al., 2002) detected via goat anti-rabbit Alexa 546-conjugated antibodies, and CD63 was revealed by mouse anti-Lamp-3 Yeast Two-Hybrid Assays followed by anti-mouse Alexa 633-conjugated antibodies. Confocal Two-hybrid library screening was performed using full-length coimages were acquired using a Zeiss LSM510 laser-scanning condon-optimized Gag (codons 1-1503) as bait fused to codons 1-147 focal microscope (Carl Zeiss Inc.), and data analysis performed of the Gal4 DNA binding domain (BD) in vector pGBKT7 (Clontech).
It is important to recognize that alternative trafficking
with MetaMorph software (Universal Imaging Corporation). Prey constructs were derived from a human HeLa cDNA library fused to the C terminus of codons 768-881 from the Gal4 activation domain in vector pACT2, and yeast 2-hybrid screening performed Electron Microscopy Transfected 293T cells or doxycycline-induced 293/Gag-Env cells according to the manufacturer's instructions (Clontech). For liquid culture assays, cells in mid-log phase were processed as described were fixed, sectioned, and stained in preparation for transmission electron microscopy as previously described (Sandefur et al., (Schneider et al., 1996) and β-galactosidase units were quantitated in a spectrophotometer. 2000). Post-embedding immunogold labeling of samples for CD63 and Gag was performed using LR white-embedded 100 nm sections essentially as previously described ( 
